Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | AGO2 | Q9UKV8 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 8/20 | 0.34 |
| ▸ | CA2 | P00918 | 8/20 | 0.34 |
| ▸ | CA12 | O43570 | 7/20 | 0.34 |
| ▸ | CA9 | Q16790 | 7/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883461 | 1.00 | TSHR (0.39) | TSHRLMNAMPOCYP3A4CYP2C9 | |
| SCHEMBL874978 | 0.82 | HSD11B1 (0.43) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL883115 | 0.82 | HSD11B1 (0.43) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL23611866 | 0.77 | F2 (0.39) | TSHRLMNAALDH1A1NT5EAGO2 | |
| SCHEMBL883462 | 0.75 | TSHR (0.44) | TSHRLMNAMPOCYP3A4CYP2C9 | |
| SCHEMBL2303282 | 0.75 | TSHR (0.44) | TSHRLMNAMPOCYP3A4CYP2C9 | |
| SCHEMBL2303076 | 0.73 | POLB (0.49) | LMNACYP3A4ALDH1A1F2PRSS1 | |
| SCHEMBL2303074 | 0.73 | POLB (0.49) | LMNACYP3A4ALDH1A1F2PRSS1 | |
| SCHEMBL2815999 | 0.73 | POLB (0.49) | LMNACYP3A4ALDH1A1F2PRSS1 | |
| SCHEMBL2300938 | 0.73 | GAA (0.43) | TSHRLMNAMPOCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359306-B2 | Process for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| EP-2350026-B1 | SULFOXIMINE SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| EP-2350026-B1 | SULFOXIMINE SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| WO-2012038411-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012038411-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-2350026-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010046035-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046035-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | WO | disclosed |
| EP-2179991-A1 | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-28 | — | — | EP | disclosed |
| EP-2179991-A1 | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | CDK6, CDK4, CDK9 | TSHR 3216/4885LMNA 4343/4885MPO 2912/4885 |
| US-20130245261-A1 | PROCESS FOR PREPARING PAN-CDK INHIBITORS OF THE FORMULA (I), AND INTERMEDIATES IN THE PREPARATION | CDK1, CDK9, CDK6 | TSHR 3781/4885LMNA 1172/4885MPO 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.